Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "TD"

1468 News Found

Apollo Hospitals acquires IFC’s 3% share in Apollo Health and Lifestyle for Rs. 1,254 Cr
News | September 13, 2025

Apollo Hospitals acquires IFC’s 3% share in Apollo Health and Lifestyle for Rs. 1,254 Cr

AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool


iRegene Therapeutics secures series B+ financing
Biotech | September 12, 2025

iRegene Therapeutics secures series B+ financing

NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation


Briefs: Torrent Pharmaceuticals and Hemant Surgical Industries
News | September 12, 2025

Briefs: Torrent Pharmaceuticals and Hemant Surgical Industries

Hemant Surgical Industries receives order


Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment
News | September 11, 2025

Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment

The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions


Novo Nordisk to cut 9,000 jobs globally
News | September 11, 2025

Novo Nordisk to cut 9,000 jobs globally

Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients


Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093
Drug Approval | September 10, 2025

Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093

MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile


Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas
News | September 10, 2025

Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas

The cGMP-4 facility will further strengthen the company's ability to serve global partners


SPL Infusion commences commercial production of new IV fluid Infusion plant
News | September 09, 2025

SPL Infusion commences commercial production of new IV fluid Infusion plant

The facility has been designed with a dual focus on efficiency and sustainability


Gilead Sciences breaks ground on new manufacturing and technical development site in US
News | September 09, 2025

Gilead Sciences breaks ground on new manufacturing and technical development site in US

New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value